Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) saw strong trading volume on Friday . 1,046,465 shares were traded during mid-day trading, an increase of 141% from the previous session’s volume of 434,181 shares.The stock last traded at $18.20 and had previously closed at $17.91.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Wednesday, April 20th. Brean Capital restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, May 16th. Finally, Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, May 3rd. Eight investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $42.50.

The stock’s 50-day moving average price is $17.93 and its 200 day moving average price is $16.12. The company’s market capitalization is $481.22 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Monday, May 2nd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.08. On average, equities analysts forecast that Aerie Pharmaceuticals Inc. will post ($2.69) EPS for the current fiscal year.

An institutional investor recently raised its position in Aerie Pharmaceuticals stock. Schroder Investment Management Group increased its position in shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 471,000 shares of the company’s stock after buying an additional 51,500 shares during the period. Schroder Investment Management Group owned approximately 1.79% of Aerie Pharmaceuticals worth $11,469,000 at the end of the most recent reporting period.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.